Biotx
biotx.ai
Bioinformatics
Drug Discovery
Drug Discovery AI
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Hoxton Ventures
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 6, 2025
Partnership Heartbeat.bio and Biotx.ai partner in heart failure · bioworld.com
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Founders and leadersfrom filings, registers and the company's site
Marco SchmidtManaging Directorscompany's site
Backed byfrom the funds' portfolios and accelerator catalogs
Hoxton Ventures Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
AI-powered gene expression models predict human tissue responses to drugs. De-risk clinical trials, optimize patient selection, and…
Vivodyne generates human data at AI scale with autonomous labs testing the most realistic human tissues ever grown outside the body.
insitro applies machine learning to human genetic and cellular data for drug discovery. Its laboratory generates large datasets…
Relation Therapeutics is a London biotechnology company founded in 2019 that applies graph machine learning to disease biology. Its…
Atomwise is a San Francisco company founded in 2012 that pioneered the use of convolutional neural networks for structure-based small…
Unlocking the full potential of chemoproteomics to accelerate the discovery of new small molecules that can change the course of disease.
News
Heartbeat.bio and Biotx.ai partner in heart failure
Heartbeat.bio AG and Biotx.ai GmbH have partnered to identify and validate novel therapeutic targets in heart failure. The collaboration combines Biotx.ai's causal mapping of the genome for target discovery with Heartbeat.bio's human-based Cardioid drug d
Read more
Report
How causal artificial intelligence is revolutionizing the pharmaceutical industry
Causal artificial intelligence (AI) is transforming the pharma business model.
Read more
Report
Simbec-Orion and biotx.ai launch strategic partnership to de-risk early-stage drug development with AI supported clinical trial design
/PRNewswire/ -- Simbec-Orion, a full-service mid-size CRO, and biotx.ai, a developer of AI-enabled causal modelling for drug development, have announced their...
Read more
Report
3Z and Biotx.ai partnership to utilize AI modeling to advance ADHD drug development
3Z ehf and Biotx.ai AG have established a strategic partnership to help advance the development of drugs for attention deficit hyperactivity disorder (ADHD). 3Z has successfully identified potential ADHD treatments through its innovative zebrafish screeni
Read more
Report
3Z and biotx.ai Forge Partnership to Advance ADHD Drug Development Using AI Modelling
REYKJAVIK, Iceland and BERLIN, Aug. 18, 2023 /PRNewswire/ -- Reykjavik-based drug discovery company, 3Z, and...
Read more
Report
Allianz SE: Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance
Anthropic's safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellence Three focus areas of the partnership: workforce empowerment, operations
Read more
Report
Report
PharmiWeb.com - Thank you
After twenty-five years, PharmiWeb.com is closing. A note of thanks to the pharmaceutical industry community that built it.
Read more
Report
People
Marco Schmidt
Managing Directors
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data